2014, FDA, Healthcare and Pharmacology

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2014

FDA

Healthcare

Pharmacology

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Legacy MEDSearch

JUNE 15, 2023

Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.

Patients

Patients Recruitment Pharmacology Side effects

The future of medical cannabis development in Europe

European Pharmaceutical Review

JULY 13, 2023

1,2 Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA). Mechoulam R.

Medical

Medical Food and Drug Administration Pharmacology Medicine

Pharma Rep Focus

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

The future of medical cannabis development in Europe

Stay Connected